![Ingmar Bruns](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Ingmar Bruns worked as the Chief Medical Officer at Trillium Therapeutics ULC from 2020 to 2021.
Prior to that, he held the position of Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns earned a doctorate degree from Universität zu Lübeck.
Antiguos cargos conocidos de Ingmar Bruns.
Empresas | Cargo | Fin |
---|---|---|
TRILLIUM THERAPEUTICS | Director Técnico/Científico/I+D | 17/11/2021 |
PIERIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formación de Ingmar Bruns.
Universität zu Lübeck | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
PIERIS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Trillium Therapeutics ULC
![]() Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Ingmar Bruns